SeaStar is a Denver-based, commercial-stage medical device company developing extracorporeal therapies built on its Selective Cytopheretic Device platform, which aims to neutralize overactive immune cells in critically ill patients. Its first commercial product received FDA approval in 2024 for pediatric use.
Veradermics is a dermatologist-founded, late-stage biopharmaceutical company based in New Haven, Connecticut. Its lead candidate, VDPHL01, is an oral, non-hormonal extended-release minoxidil tablet in Phase 3 development for pattern hair loss in men and women.
Vivani is an Alameda, California-based, clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants using its NanoPortal technology. Its lead program, NPM-139, is a semaglutide implant designed to deliver six to twelve months of continuous dosing for chronic weight management.
● Consumer discretionary was the only S&P 500 sector to finish lower.
● Evercore ISI cut its price target to $90 from $150.
● Lam Research and KLA also rallied, and Teradyne jumped after a Jefferies initiation.
● Super Micro Computer surged as servers with AMD's EPYC 9006 processors began shipping.
● Bloom raised 2026 revenue guidance to $4.4 billion to $4.6 billion.
● CoreWeave raised its 2026 revenue outlook to $13.0 billion to $13.3 billion.
● Coinbase began offering federal qualified custody after OCC approval of Coinbase National Trust.